Medistim

Transaction in Own Shares • Mar 11, 2025

Medistim ASA – Initiation of share buy-back programme

Medistim ASA – Initiation of share buy-back programme

Oslo, 11 March 2025: The Board of Directors of Medistim ASA (“Medistim” or “the Company”) has resolved to initiate a share buyback program. The share buyback program will be executed in accordance with the authorization granted to the Board of Directors by the Annual General Meeting of Medistim held on 24 April 2024.

The share buyback program will commence on 11 March 2025 and end no later than 7 May 2025, the last trading day prior to the Company’s 2025 Annual General Meeting. The share buyback program covers purchases of up to 70,000 shares, equivalent to approximately 0.38% of the Company's current share capital, with a maximum consideration of NOK 35,000,000. Shares repurchased under the program will be used in connection with the Company’s long-term share-based incentive plan for senior management.

Medistim has engaged DNB Markets, a part of DNB Bank ASA, to manage and carry out the share repurchases in the market. DNB Markets will make its trading decisions independently of, and uninfluenced by Medistim.

The share buyback program will be carried out in accordance with Regulation (EU) No 596/2014 (the "Market Abuse Regulation") and Commission Delegated Regulation (EU) No 2016/1052 (the "Safe Harbour Regulation").

The Company reserves the right to make subsequent changes to the above terms for the program and will in such case make appropriate announcements in this respect.

For further information, please contact:

Thomas Jakobsen, Chief Financial Officer, phone: +47 906 59 940

Mail: Thomas.jakobsen@medistim.com

This is information that Medistim is obliged to make public pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.